View on Pubmed.gov 34202609 | View on doi.org 10.3390/antibio...
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.
- Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy.
- Department of Internal Medicine, Pharmacology & Toxicology Unit, University of Genoa, 16100 Genoa, Italy.
Abstract
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents. The inhibitors of β-lactamases (BLI) have gained a prominent role in the safeguard of beta-lactams. In the last years, new β-lactam-BLI combinations have been registered or are still under clinical evaluation, demonstrating their effectiveness to treat complicated infections. It is also noteworthy that the pharmacokinetics of BLIs partly matches that of β-lactams companions, meaning that some clinical situations, as well as renal impairment and renal replacement therapies, may alter the disposition of both drugs. Common pharmacokinetic characteristics, linear pharmacokinetics across a wide range of doses, and known pharmacokinetic/pharmacodynamic parameters may guide modifications of dosing regimens for both β-lactams and BLIs. However, comorbidities (i.e., burns, diabetes, cancer) and severe changes in individual pathological conditions (i.e., acute renal impairment, sepsis) could make dose adaptation difficult, because the impact of those factors on BLI pharmacokinetics is partly known. Therapeutic drug monitoring protocols may overcome those issues and offer strategies to personalize drug doses in the intensive care setting. Further prospective clinical trials are warranted to improve the use of BLIs and their β-lactam companions in severe and complicated infections.
References
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
Drugs R D. 2018 Sep;18(3):221-230
Antibiotics (Basel). 2020 Jul 09;9(7):
Cited by 21 citations (total)
Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural
Non-β Lactam Inhibitors of the Serine β-Lactamase blaCTX-M15 in Drug-Resistant .
Electronic publication date November 14, 2023
Faisal Ahmad [...] Syed Sikander Azam et al.
Antibiotic resistance by bacterial pathogens against widely used β-lactam drugs is a major concern to public health worldwide, resulting in...
Journal Article
Axially chiral α-boryl-homoallenyl boronic esters as versatile toolbox for accessing centrally and axially chiral molecules.
Electronic publication date October 26, 2024
Yonghoon Jin [...] Seung Hwan Cho et al.
Axially chiral allenes bearing organoboron groups are highly sought-after building blocks in organic synthesis due to their potential for generating...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •